A meta-analysis of 5 contemporary trials found no improvement in outcomes with beta blocker therapy after myocardial infarction with normal EF (≥50%)

Conservative dialysis strategy shows promise for AKI-D The LIBERATE-D trial found that this approach led to better renal recovery at discharge vs thrice-weekly dialysis (64% vs 50%) Although adjusted CIs were nonsignificant and deaths were numerically higher

ICIs for NSCLC illustrates caution in broadening trial eligibility In ECOG 0-1, trials show overall survival gain (65% vs 50% alive at 18 mos w/ chemo) In ECOG 2+, excluded in trials & typical of hospitalized adults, survival is just ~4 mos x.com/EvidenceRounds...

Many FDA-approved drugs receive indications broader than pivotal clinical trials, most notably for patient fitness While broader labels can extend access, absolute benefits may be smaller or absent altogether, especially for sicker & more impaired hospitalized patients

The rise in early-onset cancer in the US, including colon cancer, is less an epidemic of disease & more an epidemic of diagnosis The lack of a substantial rise in deaths, despite significant rising incidence strongly suggests increased diagnostic scrutiny & overdiagnosis

Routine use of gabapentin for postoperative pain is not supported by evidence In a large multicenter double-blind RCT of patients undergoing major surgery, gabapentin did NOT improve pain, opioid use, length of stay, or quality of life confirms a prior meta-analysis

Following the topline SNAP trial results, a new multicenter trial found cefazolin noninferior to cloxacillin for MSSA bacteremia, with fewer adverse events Given its safety, convenience, and lower cost, cefazolin should be considered first-line therapy for MSSA bacteremia

You're gonna wanna follow this Will be the single best way to have your finger on the pulse of what matters in hospital medicine and inpatient medicine more broadly

Evidence Rounds@evidencerounds.bsky.social · 10mo ago

Welcome to Evidence Rounds! You might be an Evidence Rounder if you drown in literature that rarely helps and want trustworthy, curated evidence Follow for weekly updates featuring practice-changing studies and the most promising ideas that shape hospital medicine

This study seems riddled with selection and detection biases and I can't see how any knowledgeable expert could just take the results at face value and conclude a doubling of risk of long-covid with reinfection.

Eric Topol@erictopol.bsky.social · 11mo ago

Children and teens who had a Covid reinfection had a doubling of #LongCovid risk (PASC) and a significant increase in many other adverse outcomes (Figure) www.thelancet.com/journals/lan...

We had our first OFF site Division retreat last week! Incredible energy, connection & culture building Plus iconic SF views & food :) UCSF DHM based at ZSFG is becoming the best academic Division of Hospital Medicine in the country And not just for a safety-net We're hiring btw

Recent FDA actions on Covid vaccines: 1. Novavax approved (👏) 2. Narrowed indications for all (pros and cons) 3. Called for clinical trials (👍) No doubt we're relying too much on old data to inform clinical practice. Some thoughts on what we gain… and what we risk. blogs.jwatch.org/hiv-id-obser...

The Pros and Cons of the Latest FDA Actions on COVID Vaccines

In case you missed it, last week the FDA granted full approval for the Novavax COVID-19 vaccine. This vaccine, which uses a more traditional protein-plus-adjuvant strategy instead of the mRNA approach...

blogs.jwatch.org

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds sciprian@crf.org Fri, 04/25/2025 - 16:56 Michael O'Riordan SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

tctmd.com

🚨New Study in Annals🚨 GLP1ra & SGLT2i are the only diabetes meds that reduce heart attacks & death But can't work if can't prescribe TLDR 40% Medicaid enrollees have restricted access to GLP1 & 25% to SGLT2i much state/plan variability GLP access plateaued in '22 bit.ly/3Y72K2z

Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program | Annals of Internal Medicine

Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease an...

acpjournals.org

🚨New Study in Annals🚨 GLP1ra & SGLT2i are the only diabetes meds that reduce heart attacks & death But can't work if can't prescribe TLDR 40% Medicaid enrollees have restricted access to GLP1 & 25% to SGLT2i much state/plan variability GLP access plateaued in '22 bit.ly/3Y72K2z

Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program | Annals of Internal Medicine

Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease an...

acpjournals.org

Shared without comment.

I've been thinking more and more about evidence-based diagnosis Penned this piece with Gurpreet & Oanh on the SSRN preprint server titled: Striving for Diagnostic Excellence: "The Median Is Not the Message" Tell me what you think

Agree. Not enjoyable so far. Place is great if you like echo chambers, especially ones that celebrate an assassination because of the industry. Thought the selling point was more sanity and compassion? Will lurk time to time to see if gets better, but find me at the other place

Ethan Mollick@emollick.bsky.social · 2y ago

The Discover feed is pretty terrible, and I am not sure how to guide the algorithm to make it better. I know I can use various lists, but I really want a feed that includes serendipity, trends, and a broader set of topics than the one that I follow but isn't full of noise. How do you get that?

Here. But really there